ANN ARBOR, Mich.--(BUSINESS WIRE)--RetroSense Therapeutics, a privately-held, clinical-stage biotechnology company, announced today that Chief Executive Officer Sean Ainsworth will present at the 27th Annual Piper Jaffray Healthcare Conference and the Genetic RX Conference. RetroSense Therapeutics is at the forefront of developing optogenetic therapies for vision restoration. Patient recruitment is currently underway for a clinical trial investigating lead product, RST-001, for the treatment of retinitis pigmentosa, a genetic disease characterized by deteriorating vision and blindness.
